Drug Profile
APX 201
Alternative Names: APX-201Latest Information Update: 28 Oct 2023
Price :
$50
*
At a glance
- Originator Epitomics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; VISTA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 23 Aug 2023 Apexigen has been acquired and merged into Pyxis Oncology
- 05 Oct 2021 APX 201 is still in preclinical trials for Cancer in USA (Apexigen pipeline, October 2021)